Coronavirus Update: Rapid Restart For AZ’s Vaccine Trial, Pfizer Upsizes Its Phase III
UK Regulator Gives Green Light
Executive Summary
Clearance by UK regulator allows trial to restart, with pivotal US trial hoped to follow suit to keep AstraZeneca and Oxford's candidate on track for a potential late 2020 readout. Plus, new results with Sinovac's vaccine in the elderly and progress with antibodies.
You may also be interested in...
COVID Vaccine Postmarket Monitoring Will Depend On Which Adverse Events US FDA Wants To Watch
US FDA has the unenviable task of picking the most important adverse events to track once coronavirus vaccinations begin; CDC's list will need to be winnowed to 10-20 to make the surveillance feasible, and which AEs make the cut may be informed by the vaccine trials, as well as clinical experience with COVID infections.
Early Data Support J&J’s COVID-19 Vaccine Push Into Phase III
Johnson & Johnson has released early data putting its COVID-19 vaccine broadly in line with frontrunners from Pfizer and Moderna, but with key advantage of requiring just one injection.
Pfizer COVID-19 Vaccine Trial Diversity Slips As Enrollment Rises, Unlike Moderna
Trial diversity is among the issues that stakeholders worry could hinder vaccine uptake.